## Supplementary material

## **Figure Captions**

 Table S1. Molecular descriptor values of the BMLR-QSAR model for the vasodilatory active agents.

**Figure S1.** Effect of synthesized compounds and the standard reference (Amiodarone hydrochloride) on contracture induced by norepinephrine hydrochloride (NE.HCl) in rat thoracic aortic rings.

**Figure S2.** Potency (IC<sub>50</sub>, mM) of the tested compounds on contracture induced by norepinephrine hydrochloride in rat thoracic aortic rings compared with (Amiodarone hydrochloride) used as a reference standard.

Figure S3. <sup>1</sup>H NMR spectrum of 4a.

Figure S4. <sup>13</sup>C NMR spectrum of 4a.

Figure S5. <sup>1</sup>H NMR spectrum of 4b.

Figure S6. <sup>13</sup>C NMR spectrum of 4b.

**Figure S7.** <sup>1</sup>H NMR spectrum of **4c**.

Figure S8. <sup>1</sup>H NMR spectrum of 4d.

**Figure S9.** <sup>13</sup>C NMR spectrum of **4d**.

**Figure S10.** <sup>1</sup>H NMR spectrum of **4e**.

**Figure S11.** <sup>1</sup>H NMR spectrum of **4f**.

Figure S12. <sup>13</sup>C NMR spectrum of 4f.

**Figure S13.** <sup>1</sup>H NMR spectrum of **4g**.

**Figure S14.** <sup>1</sup>H NMR spectrum of **4h**.

Figure S15. <sup>13</sup>C NMR spectrum of 4h.

Figure S16. <sup>1</sup>H NMR spectrum of 4i.

Figure S17. <sup>13</sup>C NMR spectrum of 4i.

Figure S18. <sup>1</sup>H NMR spectrum of 4j.

Figure S19. <sup>13</sup>C NMR spectrum of 4j.

**Figure S20.** <sup>1</sup>H NMR spectrum of **4k**.

**Figure S21.** <sup>1</sup>H NMR spectrum of **4**I.

Figure S22. <sup>13</sup>C NMR spectrum of 4l.

Figure S23. <sup>1</sup>H NMR spectrum of 4m.

Figure S24. <sup>13</sup>C NMR spectrum of 4m.

Figure S25. <sup>1</sup>H NMR spectrum of 4n.

- **Figure S26.** <sup>13</sup>C NMR spectrum of **4n**. **Figure S27.** <sup>1</sup>H NMR spectrum of **4m**.
- **Figure S28.** <sup>1</sup>H NMR spectrum of **40**.
- **Figure S29.** <sup>1</sup>H NMR spectrum of **4p**.
- Figure S30. <sup>13</sup>C NMR spectrum of 4p.
- Figure S31. <sup>1</sup>H NMR spectrum of 4q.
- Figure S32. <sup>13</sup>C NMR spectrum of 4q.
- **Figure S33.** <sup>1</sup>H NMR spectrum of **4r**.
- **Figure S34.** <sup>1</sup>H NMR spectrum of **4s**.
- **Figure S35.** <sup>13</sup>C NMR spectrum of **4s**.
- Figure S36. <sup>1</sup>H NMR spectrum of 4t.
- **Figure S37.** <sup>1</sup>H NMR spectrum of **4u**.
- **Figure S38.** <sup>1</sup>H NMR spectrum of **4v**.
- Figure S39. <sup>13</sup>C NMR spectrum of 4v.
- Figure S40. <sup>1</sup>H NMR spectrum of 4w.
- **Figure S41.** <sup>1</sup>H NMR spectrum of **4x**.
- Figure S42. <sup>13</sup>C NMR spectrum of 4x.

Entry	Compd	Descriptors*			
		$D_1$	$D_2$	$D_3$	$D_4$
1	<b>4</b> a	196.7354	294.6783	0.00796	350.9802
2	<b>4</b> b	193.9982	266.2766	0.00769	351.0109
3	<b>4</b> c	196.7631	318.9088	0.00693	350.993
4	<b>4d</b>	193.9671	364.9057	0.00634	350.9712
5	<b>4e</b>	196.7521	283.3206	0.00708	350.9765
6	<b>4f</b>	193.9576	280.1435	0.00621	350.9558
7	<b>4</b> g	196.7126	331.4414	0.00822	350.9776
8	<b>4h</b>	193.5552	303.7959	0.00584	351.0034
9	<b>4i</b>	196.7445	309.5561	0.00817	351.0101
10	<b>4</b> j	193.5273	284.8733	0.00679	351.0018
11	<b>4</b> k	198.4084	301.8383	0.01218	351.0151
12	41	198.3929	315.658	0.01065	351.0124
13	<b>4</b> m	196.8043	256.5694	0.00756	351.0373
14	4n	194.0101	302.4001	0.00608	351.0104
15	<b>4</b> 0	196.8059	261.9922	0.01086	351.0023
16	<b>4</b> p	194.0591	256.2957	0.00759	351.0759
17	<b>4</b> q	196.6616	274.1543	0.01027	350.9653
18	4r	196.5003	255.6172	0.00738	350.9988
19	<b>4</b> s	196.7666	255.4456	0.00916	351.0069
20	<b>4</b> t	194.0979	236.8933	0.00633	351.0407
21	<b>4</b> u	196.6594	296.6829	0.01042	350.9755
22	4v	194.0351	271.8696	0.00829	350.979
23	<b>4</b> w	196.657	361.9157	0.00842	350.6562
24	<b>4</b> x	193.4009	352.4049	0.00726	350.6691

**Table S1.** Molecular descriptor values of the BMLR-QSAR model for thevasodilatory active agents.

 $*D_1$  = Max. e-e repulsion for bond C-O,  $D_2$  = WNSA-1 Weighted PNSA (PNSA1\*TMSA/1000) (MOPAC PC),  $D_3$  = FHACA Fractional HACA (HACA/TMSA) (MOPAC PC),  $D_4$  = Max. e-n attraction for bond C-N.











**Figure S1:** Effect of new chemical entities and the reference standard (Amiodarone hydrochloride) on contracture induced by norepinephrine hydrochloride (NE.HCl) in rat thoracic aortic rings.



**Figure S2.** Potency (IC<sub>50</sub>, mM) of the tested compounds on contracture induced by norepinephrine hydrochloride in rat thoracic aortic rings compared with (Amiodarone hydrochloride) used as a reference standard.







Figure S4. <sup>13</sup>C NMR spectrum of 4a.



**Figure S5.** <sup>1</sup>H NMR spectrum of **4b**.



Figure S6. <sup>13</sup>C NMR spectrum of 4b.



**Figure S7.** <sup>1</sup>H NMR spectrum of **4c**.



Figure S8. <sup>1</sup>H NMR spectrum of 4d.







Figure S10. <sup>1</sup>H NMR spectrum of 4e.











Figure S13. <sup>1</sup>H NMR spectrum of 4g.



Figure S14. <sup>1</sup>H NMR spectrum of 4h.







Figure S16. <sup>1</sup>H NMR spectrum of 4i.



Figure S17. <sup>13</sup>C NMR spectrum of 4i.



Figure S18. <sup>1</sup>H NMR spectrum of 4j.







Figure S20. <sup>1</sup>H NMR spectrum of 4k.



Figure S22. <sup>13</sup>C NMR spectrum of 4l.











Figure S27. <sup>1</sup>H NMR spectrum of 4m.



Figure S28. <sup>13</sup>C NMR spectrum of 40.



Figure S29. <sup>1</sup>H NMR spectrum of 4p.



Figure S30. <sup>13</sup>C NMR spectrum of 4p.



Figure S31. <sup>1</sup>H NMR spectrum of 4q.



Figure S32. <sup>13</sup>C NMR spectrum of 4q.



Figure S33. <sup>1</sup>H NMR spectrum of 4r.



**Figure S34.** <sup>1</sup>H NMR spectrum of **4s**.



Figure S35. <sup>13</sup>C NMR spectrum of 4s.



Figure S36. <sup>1</sup>H NMR spectrum of 4t.



Figure S37. <sup>1</sup>H NMR spectrum of 4u.



Figure S38. <sup>1</sup>H NMR spectrum of 4v.



Figure S39. <sup>13</sup>C NMR spectrum of 4v.



**Figure S40.** <sup>1</sup>H NMR spectrum of **4w**.



**Figure S41.** <sup>1</sup>H NMR spectrum of **4x**.



Figure S42. <sup>13</sup>C NMR spectrum of 4x.